Company news
Aclarion, Inc. (NASDAQ:ACON) news
Aclarion, Inc. news releases on 6ix. Latest, Aug 25, 2023: Aclarion, Inc. Announces Filing of Delayed 10-Q Quarterly Report
Press releases — page 3
Aclarion, Inc. Announces Filing of Delayed 10-Q Quarterly Report
August 24, 2023
Aclarion Announces New Commercial Engagement with The Imaging Center, Grand Rapids, MI
June 13, 2023
Aclarion Announces Statistically Significant Nociscan® Cost-Effectiveness Abstract Presented at ISASS Annual Meeting
June 7, 2023
Aclarion Announces New Engagement with The London Clinic and London Spine Clinic
May 29, 2023
Aclarion, Inc. Announces Delayed 10-Q Filing
May 22, 2023
Aclarion Announces Non-Convertible Debt Financing to Achieve Three Critical Catalysts
May 18, 2023
Aclarion Appoints Nicholas Theodore, MD as Principal Investigator for CLARITY Post-Market Trial Evaluating Nociscan in the Diagnosis and Treatment of Chronic Low Back Pain
May 1, 2023
Aclarion to Host Thought Leadership Symposium at SPINEWEEK 2023
April 27, 2023
Aclarion Announces Publication of 2YR Outcomes in Groundbreaking Clinical Trial
April 23, 2023
Aclarion Announces Alpesh Patel MD MBA as a Key Opinion Leader Physician Advisor
March 6, 2023
Gregory Basil MD to Join Aclarion as a Key Opinion Leader Surgeon Advisor
January 30, 2023
Aclarion Appoints George Frey MD as Seventh Key Opinion Leader Surgeon Advisor
January 16, 2023
Dr. Christopher Ames to Join Aclarion as a Key Opinion Leader Surgeon Advisor
December 21, 2022
Aclarion’s Key Opinion Leader Program Adds Fifth Surgeon Advisor with Addition of Eric Potts, MD
December 20, 2022
Aclarion Adds to Growing Key Opinion Leader Program with Juan Uribe M.D. as a Surgeon Advisor
December 18, 2022
Aclarion Adds to Strong Patent Portfolio with Notice of Allowance for New U.S. Patent Application Addressing Key Pain Indicator Biomarker
November 30, 2022
Dr. Sigurd Berven to join Aclarion as a Key Opinion Leader Surgeon Advisor
October 23, 2022
John Keller M.D. to Join Aclarion as a Key Opinion Leader Surgeon Advisor
October 2, 2022
Aclarion Announces Start of Healthcare Economic Analysis Study to Evaluate Financial Impact of Nociscan
July 19, 2022
Aclarion to Present 2-year Follow Up Data on Pivotal Clinical Trial Linking Nociscan to Better Surgical Outcomes for Discogenic Low Back Pain
June 21, 2022
Aclarion, Inc. Announces Closing of $9.4 Million Initial Public Offering
April 25, 2022